Mibitop (Copper Tetramibi Tetrafluoroborate)

The compound is a copper‑based complex that appears to interfere with microbial enzyme systems and generate reactive oxygen species, leading to cellular damage in pathogens. Preclinical studies also suggest modulation of immune signaling pathways, though the precise pharmacological mechanisms remain under investigation.

Dosing of Mibitop is determined by the treating investigator based on the study protocol, patient characteristics, and clinical objectives. The prescriber sets the infusion rate, volume, and frequency, and no standard commercial dosage regimen is publicly available.

Safety data for Copper Tetramibi Tetrafluoroborate in pregnant or lactating individuals are insufficient. Use during pregnancy or breastfeeding is only permitted if the potential benefit justifies the potential risk, and such decisions should be made by a qualified healthcare professional.

To request Mibitop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

As an investigational copper‑based compound, Mibitop does not have an established commercial comparator. Its proposed antimicrobial activity differs from conventional antibiotics, which target specific bacterial pathways, whereas copper complexes may exert broader oxidative mechanisms. Direct efficacy or safety comparisons are not yet available.

Mibitop should be stored refrigerated at 2–8 °C, protected from light, and kept in its original container. It must not be frozen or shaken vigorously. Prior to use, allow the solution to reach room temperature if required, and handle it using aseptic techniques in a controlled environment.

Mibitop is supplied as a sterile intravenous solution. It is administered by slow infusion through a suitable IV line under the supervision of qualified medical personnel. The infusion rate, volume, and duration are defined by the clinical protocol and the prescribing investigator.

Serious adverse reactions reported in early studies include hypersensitivity or anaphylactic responses during infusion and potential renal impairment indicated by transient increases in serum creatinine. Patients should be monitored closely for signs of allergic reaction and kidney function throughout treatment.

Individuals with known hypersensitivity to copper compounds or any component of the formulation should avoid Mibitop. Patients with severe renal dysfunction, uncontrolled infections, or those receiving concurrent nephrotoxic agents should not be administered the drug outside of a controlled research setting.